Aradigm (ARDM) Reaches New 52-Week Low at $0.68

Aradigm Co. (NASDAQ:ARDM) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $0.68 and last traded at $0.73, with a volume of 36781 shares trading hands. The stock had previously closed at $0.81.

Aradigm (NASDAQ:ARDM) last released its quarterly earnings results on Thursday, November 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03). The company had revenue of $0.28 million for the quarter. On average, sell-side analysts predict that Aradigm Co. will post -1.07 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Aradigm (ARDM) Reaches New 52-Week Low at $0.68” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2018/12/01/aradigm-ardm-reaches-new-52-week-low-at-0-68.html.

About Aradigm (NASDAQ:ARDM)

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium.

Read More: What are the risks of holding treasury bonds?

Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit